Nassim Usman, new Totus Medicines CEO

To­tus Med­i­cines clos­es $66M Se­ries B to fund ear­ly-stage PI3Ka in­hibitor, names new CEO

Small mol­e­cule biotech To­tus Med­i­cines has closed a $66 mil­lion Se­ries B to car­ry its PI3Kα in­hibitor through Phase Ia and has named Nas­sim Us­man …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.